SE0301109D0 - Nucleotide vaccine composition - Google Patents

Nucleotide vaccine composition

Info

Publication number
SE0301109D0
SE0301109D0 SE0301109A SE0301109A SE0301109D0 SE 0301109 D0 SE0301109 D0 SE 0301109D0 SE 0301109 A SE0301109 A SE 0301109A SE 0301109 A SE0301109 A SE 0301109A SE 0301109 D0 SE0301109 D0 SE 0301109D0
Authority
SE
Sweden
Prior art keywords
component
dendritic cells
bcr
positive tumor
plasmacytoid dendritic
Prior art date
Application number
SE0301109A
Other languages
Swedish (sv)
Inventor
Mallen Huang
Original Assignee
Mallen Huang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallen Huang filed Critical Mallen Huang
Priority to SE0301109A priority Critical patent/SE0301109D0/en
Publication of SE0301109D0 publication Critical patent/SE0301109D0/en
Priority to JP2006508023A priority patent/JP2006523688A/en
Priority to CN2004800164612A priority patent/CN1805758B/en
Priority to CA002522456A priority patent/CA2522456A1/en
Priority to US10/551,804 priority patent/US10799553B2/en
Priority to AT04727465T priority patent/ATE514433T1/en
Priority to PCT/SE2004/000589 priority patent/WO2004089413A1/en
Priority to EP04727465A priority patent/EP1658097B1/en
Priority to AU2004227821A priority patent/AU2004227821A1/en
Priority to US16/985,393 priority patent/US11298398B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4637—Other peptides or polypeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A method of treating a Philadelphia chromosome-positive tumor in a subject comprises administering to the subject a therapeutic composition comprising an incubated combined mixture of (a) a first component comprising (i) Philadelphia chromosome-positive tumor lysate, (ii) plasmid encoding bcr/abl fusion protein, or (iii) bcr/abl fusion peptide; and (b) a second component comprising plasmacytoid dendritic cells expressing Toll-like receptor 9 and modified for stable expression of CD40 ligand or GM-CSF by a nucleotide sequence engineered into said plasmacytoid dendritic cells.
SE0301109A 2003-04-14 2003-04-14 Nucleotide vaccine composition SE0301109D0 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (en) 2003-04-14 2003-04-14 Nucleotide vaccine composition
JP2006508023A JP2006523688A (en) 2003-04-14 2004-04-14 Nucleotide vaccine composition, nucleotide and cell vaccine composition production method, vaccine composition, vaccine composition use, immune response production method, disease treatment or prevention method, kit comprising antigen presenting cells
CN2004800164612A CN1805758B (en) 2003-04-14 2004-04-14 Nucleic acid and cellular vaccine components
CA002522456A CA2522456A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
US10/551,804 US10799553B2 (en) 2003-04-14 2004-04-14 Composition comprising a nucleotide sequence encoding an ELA2 fusion protein and plasmacytoid dendritic cells
AT04727465T ATE514433T1 (en) 2003-04-14 2004-04-14 NUCLEOTIDE AND CELLULAR VACCINE COMPOSITION
PCT/SE2004/000589 WO2004089413A1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
EP04727465A EP1658097B1 (en) 2003-04-14 2004-04-14 Nucleotide and cellular vaccine composition
AU2004227821A AU2004227821A1 (en) 2003-04-14 2004-04-14 Nucleotide vaccine composition
US16/985,393 US11298398B2 (en) 2003-04-14 2020-08-05 Method of treating a philadelphia chromosome-positive tumor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301109A SE0301109D0 (en) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Publications (1)

Publication Number Publication Date
SE0301109D0 true SE0301109D0 (en) 2003-04-14

Family

ID=20291035

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301109A SE0301109D0 (en) 2003-04-14 2003-04-14 Nucleotide vaccine composition

Country Status (9)

Country Link
US (2) US10799553B2 (en)
EP (1) EP1658097B1 (en)
JP (1) JP2006523688A (en)
CN (1) CN1805758B (en)
AT (1) ATE514433T1 (en)
AU (1) AU2004227821A1 (en)
CA (1) CA2522456A1 (en)
SE (1) SE0301109D0 (en)
WO (1) WO2004089413A1 (en)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301109D0 (en) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
US20110142887A1 (en) * 2009-12-15 2011-06-16 Immunovative Therapies Ltd. Methods and compositions for liquidation of tumors
US8513008B2 (en) 2004-10-07 2013-08-20 Argos Therapeutics, Inc. Mature dendritic cell compositions and methods for culturing same
DE602005025005D1 (en) 2004-10-07 2011-01-05 Argos Therapeutics Inc COMPOSITIONS OF RIDGE OF DENDRITIC CELLS AND METHOD OF CULTURING THEM
HUE051267T2 (en) 2005-12-13 2021-03-01 Harvard College Scaffolds for cell transplantation
WO2008065752A1 (en) * 2006-11-30 2008-06-05 National University Corporation Hokkaido University Immunotherapeutic agent containing dirna as active ingredient
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
CA2690968A1 (en) * 2007-06-19 2008-12-24 Coloplast A/S Multi-layered adhesive appliance
WO2009002401A2 (en) 2007-06-21 2008-12-31 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
US10328133B2 (en) 2008-02-13 2019-06-25 President And Fellows Of Harvard College Continuous cell programming devices
CN110075113A (en) * 2008-04-17 2019-08-02 Pds生物科技公司 Immune response is stimulated by the enantiomer of cation lipid
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
US20100330117A1 (en) * 2008-09-26 2010-12-30 Salubrious Pharmaceutical, Llc Process for treatment of amyotrophic lateral sclerosis, rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis, non-viral based cancers, alzheimers's disease, muscular dystrophy, attention deficit disorder, attention deficit hyperactivity disorder, complex regional pain syndrome, diabetes, neuropathic pain, spider arthritis, west nile virus, fibromyalgia, shingles, gout, migraine headaches, senile dementia, post polio syndrome, central virus deafness, asthma, chronic pain of unknown origin and hepatitis c
MX2011003277A (en) * 2008-10-14 2012-09-21 Salubrious Pharmaceuticals LLC Process for treatment of rheumatoid arthritis, tremors/parkinson's disease, multiple sclerosis and non-viral based cancers.
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
AU2010278702C1 (en) 2009-07-31 2016-07-14 Forsyth Dental Infirmary For Children Programming of cells for tolerogenic therapies
EP2542230A4 (en) 2010-03-05 2013-08-28 Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
WO2012048165A2 (en) 2010-10-06 2012-04-12 President And Fellows Of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
US9603894B2 (en) 2010-11-08 2017-03-28 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
US10045947B2 (en) 2011-04-28 2018-08-14 President And Fellows Of Harvard College Injectable preformed macroscopic 3-dimensional scaffolds for minimally invasive administration
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
EP2714073B1 (en) 2011-06-03 2021-03-10 President and Fellows of Harvard College In situ antigen-generating cancer vaccine
EP2802350B1 (en) * 2012-01-13 2017-12-20 President and Fellows of Harvard College Controlled delivery of tlr agonists in structural polymeric devices
PL2838515T3 (en) 2012-04-16 2020-06-29 President And Fellows Of Harvard College Mesoporous silica compositions for modulating immune responses
CN105101991A (en) 2012-09-21 2015-11-25 Pds生物科技公司 Improved vaccine compositions and methods of use
ES2949029T3 (en) * 2013-02-22 2023-09-25 Regeneron Pharma Murine cells expressing humanized major histocompatibility complex
AU2014249150B2 (en) * 2013-03-11 2020-04-02 Regeneron Pharmaceuticals, Inc. Transgenic mice expressing chimeric major histocompatibility complex (MHC) class I molecules
JP7348708B2 (en) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ Combination vaccine device and method for killing cancer cells
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
EP3280464A4 (en) 2015-04-10 2018-09-26 President and Fellows of Harvard College Immune cell trapping devices and methods for making and using the same
EP3374496A4 (en) 2015-11-13 2019-07-10 PDS Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
CN115531609A (en) 2016-02-06 2022-12-30 哈佛学院校长同事会 Remodeling hematopoietic niches to reconstitute immunity
CN115305229A (en) 2016-07-13 2022-11-08 哈佛学院院长等 Antigen presenting cell mimetic scaffolds and methods of making and using same
EP3528789A4 (en) * 2016-10-21 2020-06-24 Biosceptre UK Limited Cytotoxic particles
CN107375950B (en) * 2017-08-02 2020-10-09 深圳大学 Recombinant Gal-1 allergic environment immune tolerance induction model and establishment method
EP3810641A4 (en) * 2018-06-19 2022-07-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Oncolytic virus or antigen presenting cell mediated cancer therapy using type i interferon and cd40-ligand
CN112703004A (en) 2018-07-15 2021-04-23 伊诺奇安生物制药公司 Methods and compositions for cancer treatment using recombinant dendritic cells
CN112048007B (en) * 2020-09-11 2022-07-12 北京美康基免生物科技有限公司 Universal novel coronavirus vaccine and preparation method thereof
GB202014920D0 (en) * 2020-09-22 2020-11-04 Unikum Therapeutics Aps Methods for treating cancer and autoimmune and inflammatory diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996000255A1 (en) 1994-06-23 1996-01-04 Raymond Enterprises, Inc. Making lenticular optical systems and apparatus therefor
DE69535036T3 (en) * 1994-07-15 2011-07-07 The University of Iowa Research Foundation, IA IMMUNOMODULATIVE OLIGONUCLEOTIDES
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
US6339068B1 (en) * 1997-05-20 2002-01-15 University Of Iowa Research Foundation Vectors and methods for immunization or therapeutic protocols
AU6144499A (en) * 1998-09-15 2000-04-03 University Of Pittsburgh In situ injection of antigen-presenting cells with genetically enhanced cytokineexpression
ATE269100T1 (en) * 1998-10-05 2004-07-15 Pharmexa As METHOD FOR THERAPEUTIC VACCINATION
US6338040B1 (en) * 1999-02-12 2002-01-08 Agren, Inc. Method for delaying the development in pest species of resistance to control techniques, using insurance to encourage correct uses of refuges
CA2367692A1 (en) * 1999-03-15 2000-09-21 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
CA2309313A1 (en) * 1999-08-05 2001-02-05 Board Of Trustees Of The University Of Arkansas Stimulation of the immune response by human dendritic cell manipulation
US6780405B1 (en) 2000-04-28 2004-08-24 Avant Immunotherapeutics, Inc. Regulated antigen delivery system (RADS)
US20030202963A1 (en) * 2000-10-12 2003-10-30 Cornell Research Foundation, Inc. Method of treating cancer
US7385023B1 (en) * 2000-11-15 2008-06-10 Trustees Of Boston University Cancer immunotherapy and diagnosis using cytochrome P450 1B1
EP1350262B8 (en) * 2000-12-08 2008-08-13 Coley Pharmaceuticals GmbH Cpg-like nucleic acids and methods of use thereof
EP1423080A4 (en) * 2001-03-01 2009-06-03 Conforma Therapeutics Corp Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
AU2003223344B9 (en) 2002-03-22 2009-07-16 Zymogenetics, Inc. Anti-IL-TIF antibodies and methods of using in inflammation
US7605138B2 (en) * 2002-07-03 2009-10-20 Coley Pharmaceutical Group, Inc. Nucleic acid compositions for stimulating immune responses
EP2933334B1 (en) * 2003-02-18 2019-09-18 Baylor College of Medicine Induced activation in dendritic cells
SE0301109D0 (en) * 2003-04-14 2003-04-14 Mallen Huang Nucleotide vaccine composition
GB2402675B (en) * 2003-05-12 2008-02-20 Oxitec Ltd Resistance dilution

Also Published As

Publication number Publication date
WO2004089413A1 (en) 2004-10-21
US11298398B2 (en) 2022-04-12
CN1805758B (en) 2012-04-25
US20210077565A1 (en) 2021-03-18
CN1805758A (en) 2006-07-19
CA2522456A1 (en) 2004-10-21
EP1658097B1 (en) 2011-06-29
AU2004227821A1 (en) 2004-10-21
US10799553B2 (en) 2020-10-13
EP1658097A1 (en) 2006-05-24
US20070071722A1 (en) 2007-03-29
ATE514433T1 (en) 2011-07-15
JP2006523688A (en) 2006-10-19

Similar Documents

Publication Publication Date Title
SE0301109D0 (en) Nucleotide vaccine composition
DK1525320T3 (en) Method for Expression of Recombinant Protein in CHO Cells
BR0007414A (en) Expression and export of anti-obesity proteins as fc fusion proteins
AU4981101A (en) Subtilisin variants
WO2002016583A3 (en) Constructs and their use in metabolic pathway engineering
DK1187852T3 (en) Expression and export of interferon alpha proteins as Fc fusion proteins
LU91680I2 (en) "rilonacept and its pharmaceutically acceptable derivatives (ARCALYSR)"
RS52790B (en) Monoclonal antibodies against claudin-18 for treatment of cancer
WO2007130455A3 (en) Compositions and methods for treatment of non-hodgkins lymphoma
DK1409506T3 (en) Methods and compositions for RNAi-mediated inhibition of gene expression in mammals
MX2011006846A (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
DE69939327D1 (en) FUNCTIONAL ANTAGONISTS OF HEDGEHOG ACTIVITY
WO2006096989A3 (en) Expression vectors containing a truncated epstein barr nuclear antigen 1 lacking the gly-gly-ala domain for enhanced transient gene expression
ATE374251T1 (en) COMPOSITIONS FOR GENE THERAPY OF DIABETES
MX2023007282A (en) Ror1-specific variant antigen binding molecules.
ATE474926T1 (en) USE OF CLYA HEMOLYSIN FOR EXCRETION OF FUSION PROTEIN
AR023482A1 (en) NUCLEIC ACIDS CODING CHEMICAL POLYPEPTIDES CD40 / CD4OL, METHODS FOR THEIR PRODUCTION AND USES OF THE SAME
ATE304603T1 (en) INDUCING ALPHAVIRUS GENE EXPRESSION SYSTEM
DE69834565D1 (en) FAST GENERATION OF STABLE MAMMALIAN ANIMAL CELL LINES WITH RECOVERY OF HIGH QUANTITY OF RECOMBINANT PROTEINS
ATE527349T1 (en) NERVE REGENERATION
ATE466874T1 (en) POLYPEPTIDES RELATED TO DOMAIN 1 SCYTOVIRIN
WO2003104397A3 (en) Antisense modulation of g protein-coupled receptor kinase 6 expression
WO2004085466A3 (en) Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
AP2368A (en) Novel expression vectors and uses thereof.
AU6587998A (en) Ligand/lytic peptide compositions and methods of use